Clinical Trial

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-04-26; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2023-01-24
Trial Details
NCT Number NCT05357612
Lead Sponsor Vanderbilt University Medical Center
Collaborators: ACADIA Pharmaceuticals Inc.
Conditions Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
Enrollment 75 participants
Start Date 2023-01-23
Primary Completion 2027-06 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-07